Table 2.

Patients with PVL

Authors	Citation	Nature of study	Number of patients	Period of study	Diagnoses	Morbidity of PVL	Time to discharge after PVL in days	Mean duration to surgery	Resectability rate	Operative mortality	Liver failure	Operative morbidity	Increase of liver volume	Failure of hypertrophy	Post op stay	Disease progression
L. Mueller [33]	Ann Surg Oncol. 2008 Jul;15(7):1908–17.	R	13	1995–2004	CRC	0	NM	50.5	61.53 %	0.00 %	NM	NM	50.10 %	15 %	12	23.07 %
Capussoti [35]	Arch Surg 2008 Oct;143(10):978-82; discussion 982	R	17	2000–2006	CRC	0	median = 10	13–135 days (median = 40 days)	64.75 %	0	NM	38.46 %	43.10 %	0	6–30 days (median = 15 days)	35.30 %
Broering [41]	J Gastroint Surg 2002 Nov-Dec;6(6):905–13; discussion 913.	R	17	1995–2000	CRC 10, HCC 1, CC 6	5.80 %	8.1+/−5.1	83+/−30 days	58.825	0	NM	27 %	43.20 %	17.64 %	12.2+/−6.72 days	41.17 %
Belghiti [42]	J Gastroint Surg 2008 Feb;12(2):297–303. Epub 2007 Nov 30	P	17	1998–2005	CR :7, NET10	23.52 %	13+/−6	7–8 weeks	72 %	0	14.28 %	36 %	38+/−26 %	11.76 %	na	11.76 %
Are [43]	HPB (Oxford). 2008;10(4):229–33	R	9	2005–2007	CRC 5, HCC 1, CC:3	0	6.7+/−1.4	NM	55 %	NM	NM	NM	181.50 %	0	na	44.44 %
Kianmanesh [44]	J Am Coll Surg. 2003 Jul;197(1):164–70.	R	20	1996–2001	CRC 12; NET 8	5 %	6–20 days	4–8 weeks (median = 6 weeks)	70 %	0	0	0	32+/−9 %	0	13 days	20 %

R retrospective, P prospective, NM not mentioned, CRC colorectal liver metastasis, HCC hepato-cellular cancer, CC cholangiocellular cancer, GBCa gall bladder cancer, NET neuro-endocrine tumour, OM other metastatic lesions